News
Olon USA Prepares for AAPS PharmSci 360: Showcasing API Development Expertise
As Olon USA gears up for AAPS PharmSci 360 in Salt Lake City from October 20-23, 2024, we’re…
Enhancing Drug Innovation Through the Power of Small-Scale Chemistry
Reliable drug discovery and development is essential in the quickly changing biotech and pharmaceutical industries. Small-scale chemistry plays…
Flexible API Production: How Our Kilo Lab at Olon USA Supports Small Pharma
The pharmaceutical industry is constantly evolving. A key part of a pharmaceutical company’s success is both efficient and…
OLON CONTINUES ITS GROWTH PATH AND ANNOUNCES A NEW ACQUISITION
OLON CONTINUES ITS GROWTH PATH AND ANNOUNCES A NEW ACQUISITION Olon, the leading chemical-pharmaceutical group in the production…
Olon USA’s Expertise in Custom Stable-Labeled Bioanalytical Standards for Drug Development
Olon USA’s expertise in stable labeling empowers clients to develop cost-effective and precise bioanalytical internal standards. As a…
Finding the Needle in the Haystack with Impurity Isolation and Characterization
Impurity isolation and characterization is a broad area of analytical services integral to the development process for drugs…
Olon USA Heads to Milan: What to Expect from Us at CPHI Worldwide 2024
As the pharmaceutical world prepares for one of its premier events, CPHI Worldwide in Milan, Italy, Olon USA…
Olon Expands Capabilities with Acquisition of GTP Bioways
We are thrilled to announce that Olon Group, our parent company, has acquired GTP Bioways Group, a leading…
OLON GROUP ANNOUNCES THE ACQUISITION OF GTP BIOWAYS GROUP
GTP Bioways Group is a French company operating as Biotech CDMO (Contract Developing and Manufacturing Organisation), specialising in…
From Lab to Market: Olon USA’s Chemical Development Expertise
At Olon USA, we excel in providing comprehensive chemical development services designed to take your project from early…
The State of the Pharmaceutical Industry: Olon USA’s Approach to Accelerating Drug Development
As we move into the third quarter of 2024, the pharmaceutical industry is witnessing a significant resurgence. The…
OLON GROUP IS AMONG THE SIGNATORS OF THE MANIFESTO “BUSINESSES FOR PEOPLE AND SOCIETY”
Olon is pleased to announce that it has signed the “Businesses for People and Society” Manifesto, the text…
Individualized Local Chemical Services from a Global Source
Olon is a global leader in the development and manufacturing of API from pre-clinical to commercial. With eleven…
Exploring Innovation: Olon USA’s Presence at BIO International Convention
Olon USA, a seasoned participant at the BIO International Convention, brings a wealth of experience and innovation to…
Empowering Pharmaceutical Development: Connect with Olon USA at CPHI North America
Olon USA is excited to announce our participation in CPHI North America, a premier gathering for professionals in…
Driving Success in the Pharmaceutical Industry: An Interview with Nerissa Chu-A-Kong, Olon USA’s Business Development Director
In the fast-paced and ever-evolving pharmaceutical industry, professionals like Nerissa Chu-A-Kong are the driving force behind innovation and…
We celebrate excellence!
Olon has been selected as Champion of 2024 CDMO Leadership Awards and won the recognition of the category…
Olon USA Analytical Services: Located in Ohio, Backed By Worldwide Expertise
The realm of chemical analysis and drug development is both competitive and fast-paced. Companies looking to access reliable…
Meet with Olon USA and Olon Decision-Makers at DCAT Week, March 18-21
Reserve a Meeting Time Now for an On-the-Spot Agreement Operating in the highly competitive biopharma niche, the one…
Overcoming API Development Challenges: How Olon USA Stands Out
Active Pharmaceutical Ingredient (API) consultants are pivotal in navigating the complexities of drug manufacturing and regulatory compliance in…
Navigating the Dynamic Landscape of Drug Development: A Conversation with Brent Saba, Olon USA’s Director of Business Development
In the dynamic world of drug development, staying ahead of industry changes is paramount. We had the privilege…
Expanding Capabilities for Clients: Olon to Open New High Potency API Suite in the U.S.
In the ever-evolving world of pharmaceuticals, Olon continues to push the boundaries of what’s possible. We’re excited to…
Olon Group discloses that, as of January 1, 2024, Olon USA LLC, Concord, OH and Olon USA Inc. commercial offices, based in Florham Park, NJ, have merged to become Olon USA LLC.
Olon Group discloses that, as of January 1, 2024, Olon USA LLC, Concord, OH and Olon USA Inc.…
Embracing Growth and Next-Level Leadership: Olon Unveils New Era with Merger and Rebranding as Olon USA
On January 1, 2024, Olon USA LLC and Olon USA Inc. joined forces. This merger and rebranding as…
The Successes for Olon in 2023 and What it Means for Our Customers in 2024
The end of a year brings with it an opportunity for reflection and learning in which we take…
Olon USA: Agility and Expertise for Your Pharmaceutical Development Project
Oftentimes, in the pursuit of cost-effective and efficient manufacturing solutions, pharmaceutical development companies find themselves grappling with unforeseen…
The Olon Ricerca Approach: Unbiased Analytical Expertise in Pharmaceutical Testing for Intellectual Property Law
In the pharmaceutical research and development space, intellectual property (IP) infringement can inflict substantial damage on companies. Just…
OLON OFFICIALLY OPENS ITS NEW RESEARCH AND DEVELOPMENT CENTRE,CORNERSTONE OF ITS GLOBAL R&D NETWORK
Investment of EUR 10 million in the industrial site in Rodano (Milan), Olon’s headquarters, with 50 new jobs,…
Driving Success in the Pharmaceutical Industry: An Interview with Olon’s Head of Business Development, Western US, Molly Gleizes
In the rapidly evolving world of pharmaceuticals and biotechnology, business development plays a crucial role in forging successful…
NEW EXPANSION PLAN FOR OLON INDIAN SITE THAT WILL INCREASE ITS TOTAL PRODUCTION CAPACITY BY 45%
Milan, Italy – November 09, 2023 – Olon Group, a world leader in the production of APIs, announces…
OLON, API SUPPLIER OF THE YEAR
It has been an outstanding CPHI for Olon, it achieved an incredible success at 2023 Global Generic and…
CPHI WW 2023, OLON ANNOUNCES A FURTHER SIGNIFICANT EXPANSION OF ITS GENERIC PIPELINES
On the occasion of CPhI Worldwide 2023 (Barcelona, 24 – 26 Oct), the most important international event of…
New production area for the industrial-scale production of proteins from alternative sources
The Group announced the completion of works and the finalisation of a new production area at the Settimo…
OLON RELEASES ITS ANNUAL SUSTAINABILITY REPORT
Milan, Italy, October 5, 2023 – Olon is proud to publish its annual Corporate Sustainability Report, which details…
Unlocking Innovations and Collaborations: Olon’s Journey to CPHI Worldwide 2023 in Barcelona
Olon USA is thrilled to announce its upcoming participation in the annual CPHI Worldwide 2023 event, scheduled to…
Olon USA at AAPS 2023: Partnering for Pharmaceutical Innovation
We are delighted to announce Olon USA’s participation in the highly anticipated American Association of Pharmaceutical Scientists (AAPS)…
Your Development Roadmap Begins With Olon Ricerca
Many smaller and start-up pharma companies may have a concept of a molecule they want to develop, and…
Analytical Services to Meet & Exceed Your Needs
At Olon USA, we value collaborating with our customers throughout the project life cycle. We understand each stage…
We Can Do More Than You Think in the U.S.
In today’s ever-changing global geopolitical environment, businesses face numerous concerns about their reliance on foreign countries, particularly in…
High-resolution mass spectrometry: a powerful technology in drug discovery and process development
In the last decade, high-resolution mass spectrometry (HRMS) has emerged as a powerful technique in many fields of…
MAHAD SITE INCREASES ITS FERMENTATION CAPACITY
Olon announces a new investment to further increase the production capacity, in one of the facilities dedicated to…
Don’t Miss Your Opportunity to Connect with Olon USA at the 2023 BIO International Convention in Boston!
As the highly anticipated BIO trade show approaches, Olon USA is gearing up to make a significant impact.…
OLON ENTERS IN ADC MARKET
Milan, Italy – XXX May 2023 – OLON Group, a global leader in the development and production of…
Olon – further milestone in its plan to expand and increase production capacity
Olon, global leader in the development and production of active pharmaceutical ingredients (APIs) for CDMO and generic markets,…
One year after the launch of the international network of Biocatalysis, Olon has achieved the developing a new production process through engineering target enzyme
Milan, 10th Maj 2023 – One year after the launch of the International Network for Biocatalysis, an innovative…
Generics Bulletin interviews our CEO Paolo Tubertini
With Olon investing significantly in its production capacity and technical capabilities, CEO Paolo Tubertini believes the API specialist…
Interview to Robert Poe, CEO Olon USA, published on Global Business Report
“What we are doing here is beginning the build-out of a high-potency API suite, so that we can…
OLON ANNOUNCES THAT ITS RIFAMPICIN DMF IS ELIGIBLE FOR GDUFA PRIOR ASSESSMENT AND IT MEETS THE REQUIREMENTS FOR NITROSAMINE STANDARDS
Within the framework of a consolidated and pioneering regulatory strategy, Olon announces that its Rifampicin Drug Master File…
OLON HAS BEEN SELECTED AS CHAMPION IN FIVE CATEGORIES OF 2023 CDMO LEADERSHIP AWARDS
Milan, Italy, 17 th March 23, 2023 — Olon Group, global leader in the development and production ofactive pharmaceutical ingredients…
Olon announces the completion of the investment to expand the pilot plant capacity in Rodano plant
Olon is pleased to announce the completion of the investment in its Rodano facility to expand the pilot…